Biotech Stocks to Watch: Recovery Potential for 3 Firms

Emerging Recovery: Investors eye biotech stocks CRISPR, Amgen, and Regeneron for potential rebounds after underperformance. Despite challenges, these companies show promise for recovery based on their pipeline and market opportunities.

Date: 10-02-2025

AI Rating: 6

**Earnings and Performance Overview**

The report highlights three biotech companies—CRISPR Therapeutics, Amgen, and Regeneron Pharmaceuticals—that have faced challenging conditions in the market but have potential for recovery. Notably, CRISPR Therapeutics has minimal revenue and remains unprofitable, marking a high-risk investment despite its innovative capabilities and promising pipeline.

**CRISPR Therapeutics** currently lacks significant Earnings Per Share (EPS) due to its unprofitability and minimal revenues. However, the FDA's granting of RMAT designation for its CTX112 indicates potential for future earnings growth. Investors remain skeptical, but the company's pipeline could yield promising results if clinical and regulatory progress continues.

**Amgen** shows a contrast to CRISPR, as the company possesses a deep lineup of products poised for revenue growth. Despite setbacks with its weight-loss candidate MariTide, Amgen's pipeline and ongoing clinical trials suggest that it might deliver strong financial results in the long run. The company has also stated a significant history of dividend growth, which may provide stability to long-term investors.

**Regeneron** stands out as it reported total revenue of $3.79 billion, marking a solid 10% increase from the previous year, reflecting both revenue growth and effective revenue management through its key products, Dupixent, and Eylea. However, it faces challenges in market competition for Eylea, which could affect future revenue growth. Nonetheless, the growth of Dupixent in new indications could mitigate risks from competition.

Overall, the presence of revenue growth and a focus on innovative drug development among these companies suggests that, while some factors point to challenges, the long-term recovery potential exists, especially in the context of the drug engineering and biotech sectors.

Stocks: NASDAQ:CRSP NASDAQ:AMGN NASDAQ:REGN